Increased cytotoxicity of ionizing radiation in combination with membrane-targeted apoptosis modulators involves downregulation of protein kinase B/Akt-mediated survival-signaling

被引:30
作者
Handrick, Rene
Rubel, Amelie
Faltin, Heidrun
Eibl, Hansjorg
Belka, Claus
Jendrossek, Verena
机构
[1] Univ Tubingen, Dept Radiat Oncol Expt Radiat Oncol, D-72076 Tubingen, Germany
[2] Max Planck Inst Biophys Chem, D-37077 Gottingen, Germany
关键词
erucylphosphocholine; erufosine; apoptosis; protein kinase B; FOXO3A; Bcl-2; proteins;
D O I
10.1016/j.radonc.2006.07.021
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and purpose: The membrane-targeted apoptosis modulators erucylphosphocholine (ErPC) and erucylphosphohomocholine (ErPC3) induce apoptosis in highly apoptosis resistant malignant glioma cell lines and enhance radiation-induced cell death and eradication of clonogenic tumor cells in vitro. Aim of the present study was to elucidate molecular mechanisms of combined action. Materials and methods: Induction of apoptosis was evaluated by determination of nuclear morphology (fluorescence microscopy), alteration of mitochondrial function and caspase-activation (flow cytometry, Western blot). Activity of protein kinase B (PKB/Akt) and key downstream effectors involved in apoptosis regulation was verified by Western blot analysis using activation-specific antibodies. Results: Increased cytotoxicity of the combination was linked to a more efficient activation of the intrinsic apoptosis pathway with increased damage of the mitochondria and caspase-activation. Moreover, activity of the survival kinase PKB/Akt was downregulated upon treatment with ErPC/ErPC3 alone or in combination with ionizing radiation. Inhibition of PKB/Akt was associated with decreased phosphorylation and thus activation of the pro-apoptotic Bcl-2 protein Bad as well as dephosphorylation of the transcription factor FOXO3A (FKHRL1) that may be responsible for the observed increased expression of the pro-apoptotic Bcl-2 protein Bim. Conclusions: Our data suggest a role for inhibition of PKB/Akt-mediated anti-apoptotic signaling in increased efficacy of the combination. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:199 / 206
页数:8
相关论文
共 40 条
[1]  
Afra D, 2002, LANCET, V359, P1011
[2]   Apoptosis-modulating agents in combination with radiotherapy-current status and outlook [J].
Belka, C ;
Jendrossek, V ;
Pruschy, M ;
Vink, S ;
Verheij, M ;
Budach, W .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 58 (02) :542-554
[3]   Differential role of caspase-8 and BID activation during radiation- and CD95-induced apoptosis [J].
Belka, C ;
Rudner, J ;
Wesselborg, S ;
Stepczynska, A ;
Marini, P ;
Lepple-Wienhues, A ;
Faltin, H ;
Bamberg, M ;
Budach, W ;
Schulze-Osthoff, K .
ONCOGENE, 2000, 19 (09) :1181-1190
[4]   State-of-the-art treatment of high-grade brain tumors [J].
Brandes, AA .
SEMINARS IN ONCOLOGY, 2003, 30 (06) :4-9
[5]   Guardians of cell death:: the Bcl-2 family proteins [J].
Daniel, PT ;
Schulze-Osthoff, K ;
Belka, C ;
Güner, D .
PROGRAMMED CELL DEATH, 2003, 39 :73-88
[6]   Oligomeric Bax is a component of the putative cytochrome c release channel MAC, mitochondrial apoptosis-induced channel [J].
Dejean, LM ;
Martinez-Caballero, S ;
Guo, L ;
Hughes, C ;
Teijido, O ;
Ducret, T ;
Ichas, F ;
Korsmeyer, SJ ;
Antonsson, B ;
Jonas, EA ;
Kinnally, KW .
MOLECULAR BIOLOGY OF THE CELL, 2005, 16 (05) :2424-2432
[7]   Increased delivery of erucylphosphocholine to C6 gliomas by chemical opening of the blood-brain barrier using intracarotid pentylglycerol in rats [J].
Erdlenbruch, B ;
Jendrossek, V ;
Kugler, W ;
Eibl, H ;
Lakomek, M .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2002, 50 (04) :299-304
[8]   Erucylphosphocholine: pharmacokinetics, biodistribution and CNS-accumulation in the rat after intravenous administration [J].
Erdlenbruch, B ;
Jendrossek, V ;
Gerriets, A ;
Vetterlein, F ;
Eibl, H ;
Lakomek, M .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1999, 44 (06) :484-490
[9]   Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells [J].
Essafi, A ;
de Mattos, SF ;
Hassen, YAM ;
Soeiro, I ;
Mufti, GJ ;
Thomas, NSB ;
Medema, RH ;
Lam, EWF .
ONCOGENE, 2005, 24 (14) :2317-2329
[10]  
Gajate C, 2000, INT J CANCER, V85, P674, DOI 10.1002/(SICI)1097-0215(20000301)85:5<674::AID-IJC13>3.0.CO